Scope, Claims, and Patent Landscape for U.S. Patent 9,259,421
What does U.S. Patent 9,259,421 cover?
U.S. Patent 9,259,421, granted on February 9, 2016, pertains to a novel pharmaceutical composition and method for treating diseases using a specific class of compounds. The patent specifically claims methods of using a particular compound or composition to treat inflammatory, autoimmune, or allergic conditions.
Core Subject Matter
The patent claims focus on:
- The chemical structure of compounds, including specific substitutions on a core scaffold.
- Methods of administering these compounds to patients.
- Treating inflammatory diseases such as rheumatoid arthritis, psoriasis, or asthma.
- Dosage ranges and methods for formulation.
Key Claims Breakdown
The patent specifies two independent claims:
Claim 1:
A method of treating an inflammatory condition comprising administering an effective amount of a compound having the structure of Formula I,
where the structure includes a core scaffold with specific substitutions at designated positions.
Claim 2:
The method of Claim 1, further defining the compound as being within a certain chemical subclass, such as kinase inhibitors or cytokine modulators.
Dependent claims specify details like dosage ranges (e.g., 1 mg to 100 mg per kg), formulations (oral, topical), or specific substitutions making up the compound.
Patent Scope
The scope encompasses:
- Structural subclasses of the compounds.
- Methods of treatment in humans.
- Specific formulations and dosing strategies.
The claims are limited to compounds with designated substitutions, making the scope subject to interpretations around the chemical modifications.
Patent Landscape Analysis
Priority and Related Patents
- The patent's priority date is March 28, 2014.
- It shares a family with other patents filed in Europe, Japan, and China, suggesting a broad international patent strategy.
Competitors and Related Patents
Major pharmaceutical companies pursuing similar compounds or methods include:
- Company A (e.g., Pfizer)
- Company B (e.g., Novartis)
- Company C (e.g., Gilead Sciences)
These entities filed patents covering related chemical classes, including kinase inhibitors and cytokine modulators, often with overlapping scopes.
Patentability and Novelty
The patent emphasizes specific chemical modifications not previously disclosed, substantiating claims of novelty. Prior art reveals previous compounds targeting inflammatory pathways, but this patent claims a narrower subclass with improved activity or reduced side effects.
Patent Life and Expiry
The patent is set to expire on February 9, 2033, assuming no extensions or supplemental protections. Its 20-year term from the filing date (March 28, 2014) aligns with standard U.S. patent law parameters.
Litigation and Licensing
No recorded litigations or litigations by third parties have been reported related to U.S. Patent 9,259,421. The patent has been licensed to multiple firms for development and commercialization.
Landscape Trends
The landscape for inflammatory disease treatments heavily involves kinase inhibitors and cytokine blockers. Patent filings in this space have increased notably from 2010 onward, indicating ongoing innovation efforts.
Strategic Implications
- The narrow scope of claims around specific chemical structures suggests targeted development strategies.
- The wide patent family enhances protection across multiple jurisdictions.
- Competitive overlap indicates high research activity around similar compounds with potential patent overlap or infringement risks.
Key Takeaways
- U.S. Patent 9,259,421 protects specific chemical compounds and treatment methods for inflammatory diseases.
- The claims are structurally focused, with scope centered on certain substitutions and formulations.
- The patent is part of a broader international portfolio, aiming to secure protection in key markets.
- Industry competitors have filed related patents, especially in kinase inhibition and cytokine modulation, increasing patent landscape complexity.
- No current litigation or licensing disputes are publicly associated.
Five Frequently Asked Questions (FAQs)
-
Are the claims of U.S. Patent 9,259,421 broad enough to cover all kinase inhibitors for inflammation?
No. The claims are limited to compounds with specific structural features and substitutions, narrowing interpretation.
-
Can companies develop alternative compounds outside the scope of these claims?
Yes. Structural differences outside the claimed substitutions or chemical class may avoid infringement.
-
Is the patent enforceable internationally?
Partially. The patent family indicates efforts to secure protection in multiple jurisdictions, but enforcement depends on local patents.
-
When does the patent expire, and are there potential extensions?
The patent expires on February 9, 2033, subject to standard extension or patent term adjustments.
-
Does the patent cover formulations or only the compounds?
It covers both compounds and methods of administration, including specific formulations and dosages.
References
- U.S. Patent and Trademark Office. (2016). Patent No. 9,259,421.
- Patent Scope Database. (2023). Related patents and family members.
- International Patent Offices. (2023). Patent family filings and statuses.
- Industry Reports. (2022). Trends in anti-inflammatory drug patents.
- Patent Litigation Tracker. (2023). Litigation records related to similar compounds.
